IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 21/12/2024

SEK10.90

−0.35 (−3.11%)

Market capitalisation

SEK565m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

Latest Insights

View More

Healthcare | Update

IRLAB Therapeutics — Progress across the pipeline in Q324

Healthcare | Flash note

IRLAB Therapeutics — IRL757 starts strong in Phase I

IRLAB Therapeutics_resized

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Kristina Torfgård

    CEO

  • Kristina Torfgård

    CEO

  • Viktor Siewertz

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free